The two peptide lantibiotic lacticin 3147 acts synergistically with polymyxin to inhibit Gram negative bacteria

BMC Microbiology

R Paul Ross²  Colin Hill¹  Paul D Cotter²  Lorraine A Draper³ 

[1] Alimentary Pharmabiotic Centre, University College Cork, Cork, Ireland;Teagasc Food Research Centre, Moorepark, Fermoy, County Cork, Ireland;Department of Microbiology, University College Cork, Cork, Ireland

关键词: Polymyxin;    Lacticin 3147;    Bacteriocin;    Lantibiotic;    Synergy;    Antimicrobial;   

Others  :  1143008
DOI  :  10.1186/1471-2180-13-212

 received in 2013-08-07, accepted in 2013-09-19,  发布年份 2013

【 摘 要 】

Background

The emergence of bacterial drug resistance encourages the re-evaluation of the potential of existing antimicrobials. Lantibiotics are post-translationally modified, ribosomally synthesised antimicrobial peptides with a broad spectrum antimicrobial activity. Here, we focussed on expanding the potential of lacticin 3147, one of the most studied lantibiotics and one which possesses potent activity against a wide range of Gram positive species including many nosocomial pathogens. More specifically, our aim was to investigate if lacticin 3147 activity could be enhanced when combined with a range of different clinical antibiotics.

Results

Initial screening revealed that polymyxin B and polymyxin E (colistin) exhibited synergistic activity with lacticin 3147. Checkerboard assays were performed against a number of strains, including both Gram positive and Gram negative species. The resultant fractional inhibitory concentration (FIC) index values established that, while partial synergy was detected against Gram positive targets, synergy was obvious against Gram negative species, including Cronobacter and E. coli.

Conclusions

Combining lacticin 3147 with low levels of a polymyxin could provide a means of broadening target specificity of the lantibiotic, while also reducing polymyxin use due to the lower concentrations required as a result of synergy.

【 授权许可】

   
2013 Draper et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Cotter PD, Ross RP, Hill C: Bacteriocins - a viable alternative to antibiotics? Nat Rev Microbiol 2013, 11:95-105.
• [2]Piper C, Cotter PD, Ross RP, Hill C: Discovery of medically significant lantibiotics. Curr Drug Discov Technol 2009, 6:1-18.
• [3]Chatterjee C, Paul M, Xie L, van der Donk WA: Biosynthesis and mode of action of lantibiotics. Chem Rev 2005, 105:633-684.
• [4]Bierbaum G, Sahl HG: Lantibiotics: mode of action, biosynthesis and bioengineering. Curr Pharm Biotechnol 2009, 10:2-18.
• [5]Suda S, Cotter PD, Hill C, Ross RP: Lacticin 3147–biosynthesis, molecular analysis, immunity, bioengineering and applications. Curr Protein Pept Sci 2012, 13:193-204.
• [6]Morgan SM, O'Connor PM, Cotter PD, Ross RP, Hill C: Sequential actions of the two component peptides of the lantibiotic lacticin 3147 explain its antimicrobial activity at nanomolar concentrations. Antimicrob Agents Chemother 2005, 49:2606-2611.
• [7]Wiedemann I, Bottiger T, Bonelli RR, Wiese A, Hagge SO, Gutsmann T, Seydel U, Deegan L, Hill C, Ross P, Sahl HG: The mode of action of the lantibiotic lacticin 3147–a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. Mol Microbiol 2006, 61:285-296.
• [8]Carroll J, Draper LA, O'Connor PM, Coffey A, Hill C, Ross RP, Cotter PD, O'Mahony J: Comparison of the activities of the lantibiotics nisin and lacticin 3147 against clinically significant mycobacteria. Int J Antimicrob Agents 2010, 36(2):132-136.
• [9]Rea MC, Clayton E, O'Connor PM, Shanahan F, Kiely B, Ross RP, Hill C: Antimicrobial activity of lacticin 3,147 against clinical Clostridium difficile strains. J Med Microbiol 2007, 56:940-946.
• [10]Iancu C, Grainger A, Field D, Cotter P, Hill C, Ross RP: Comparison of the potency of the lipid II targeting antimicrobials nisin, lacticin 3147 and vancomycin against Gram-positive bacteria. Probiotics Antimicrob Proteins 2012, 4:108-115.
• [11]Storm DR, Rosenthal KS, Swanson PE: Polymyxin and related peptide antibiotics. Annu Rev Biochem 1977, 46:723-763.
• [12]Ohzawa R: The use of colimycin ear drops. Jibiinkoka 1965, 37:585-590.
• [13]Nakajima S: Clinical use of colimycin F otic solution. Jibiinkoka 1965, 37:693-697.
• [14]Velkov T, Thompson PE, Nation RL, Li J: Structure–activity relationships of polymyxin antibiotics. J Med Chem 2010, 53:1898-1916.
• [15]Vaara M: Agents that increase the permeability of the outer membrane. Microbiol Rev 1992, 56:395-411.
• [16]Morrison DC, Jacobs DM: Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry 1976, 13:813-818.
• [17]Srimal S, Surolia N, Balasubramanian S, Surolia A: Titration calorimetric studies to elucidate the specificity of the interactions of polymyxin B with lipopolysaccharides and lipid A. Biochem J 1996, 315(Pt 2):679-686.
• [18]Hancock RE: The bacterial outer membrane as a drug barrier. Trends Microbiol 1997, 5:37-42.
• [19]Falagas ME, Kasiakou SK: Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006, 10:R27. BioMed Central Full Text
• [20]Evans ME, Feola DJ, Rapp RP: Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant Gram-negative bacteria. Ann Pharmacother 1999, 33:960-967.
• [21]Falagas ME, Kasiakou SK: Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005, 40:1333-1341.
• [22]Zavascki AP, Goldani LZ, Li J, Nation RL: Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 2007, 60:1206-1215.
• [23]Yuan Z, Tam VH: Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms. Expert Opin Investig Drugs 2008, 17:661-668.
• [24]Pietschmann S, Hoffmann K, Voget M, Pison U: Synergistic effects of miconazole and polymyxin B on microbial pathogens. Vet Res Commun 2009, 33:489-505.
• [25]Giamarellos-Bourboulis EJ, Sambatakou H, Galani I, Giamarellou H: In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa. J Chemother 2003, 15:235-238.
• [26]Giamarellos-Bourboulis EJ, Xirouchaki E, Giamarellou H: Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2001, 40:117-120.
• [27]Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME: Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005, 49:3136-3146.
• [28]Hoiby N, Frederiksen B, Pressler T: Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 2005, 4(Suppl 2):49-54.
• [29]Vidaillac C, Benichou L, Duval RE: In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 2012, 56:4856-4861.
• [30]Yahav D, Farbman L, Leibovici L, Paul M: Colistin: new lessons on an old antibiotic. Clin Microbiol Infect 2012, 18:18-29.
• [31]Naghmouchi K, Drider D, Baah J, Teather R: Nisin A and polymyxin B as synergistic inhibitors of Gram-positive and Gram-negative bacteria. Probiotics Antimicrob Proteins 2010, 2:98-103.
• [32]Naghmouchi K, Belguesmia Y, Baah J, Teather R, Drider D: Antibacterial activity of class I and IIa bacteriocins combined with polymyxin E against resistant variants of Listeria monocytogenes and Escherichia coli. Res Microbiol 2011, 162:99-107.
• [33]Giacometti A, Cirioni O, Barchiesi F, Fortuna M, Scalise G: In vitro activity of cationic peptides alone and in combination with clinically used antimicrobial agents against Pseudomonas aeruginosa. J Antimicrob Chemother 1999, 44:641-645.
• [34]Oshima S, Rea MC, Lothe S, Morgan S, Begley M, O'Connor PM, Fitzsimmons A, Kamikado H, Walton R, Ross RP, Hill C: Efficacy of organic acids, bacteriocins, and the lactoperoxidase system in inhibiting the growth of Cronobacter spp. in rehydrated infant formula. J Food Prot 2012, 75:1734-1742.
• [35]Piper C, Draper LA, Cotter PD, Ross RP, Hill C: A comparison of the activities of lacticin 3147 and nisin against drug-resistant Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother 2009, 64:546-551.
• [36]Naghmouchi K, Baah J, Hober D, Jouy E, Rubrecht C, Sane F, Drider D: Synergistic effect between colistin and bacteriocins in controlling Gram-negative pathogens and their potential to reduce antibiotic toxicity in mammalian epithelial cells. Antimicrob Agents Chemother 2013, 57:2719-2725.
• [37]Gales AC, Reis AO, Jones RN: Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001, 39:183-190.
• [38]Hermsen ED, Sullivan CJ, Rotschafer JC: Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Infect Dis Clin North Am 2003, 17:545-562.
• [39]Klostermann K, Crispie F, Flynn J, Meaney WJ, Ross RP, Hill C: Efficacy of a teat dip containing the bacteriocin lacticin 3147 to eliminate Gram-positive pathogens associated with bovine mastitis. J Dairy Res 2010, 77:231-238.
• [40]Ryan MP, Meaney WJ, Ross RP, Hill C: Evaluation of lacticin 3147 and a teat seal containing this bacteriocin for inhibition of mastitis pathogens. Appl Environ Microbiol 1998, 64:2287-2290.
• [41]Shpigel NY, Elazar S, Rosenshine I: Mammary pathogenic Escherichia coli. Curr Opin Microbiol 2008, 11:60-65.
• [42]Schukken Y, Chuff M, Moroni P, Gurjar A, Santisteban C, Welcome F, Zadoks R: The "other" Gram-negative bacteria in mastitis: Klebsiella, Serratia, and more. Vet Clin North Am Food Anim Pract 2012, 28:239-256.
• [43]Hogan JS, Smith KL: A practical look at environmental mastitis. Comp Cont Educ Pract 1987, 9:F341-F346.
• [44]Arduino RC, Murray BE, Rakita RM: Roles of Antibodies and Complement in Phagocytic Killing of Enterococci. Infection and Immunity 1994, 62:987-993.
• [45]Cotter PD, Draper LA, Lawton EM, McAuliffe O, Hill C, Ross RP: Overproduction of wild-type and bioengineered derivatives of the lantibiotic lacticin 3147. Appl Environ Microbiol 2006, 72:4492-4496.
• [46]Collins B, Curtis N, Cotter PD, Hill C, Ross RP: The ABC transporter AnrAB contributes to the innate resistance of Listeria monocytogenes to nisin, bacitracin, and various beta-lactam antibiotics. Antimicrob Agents Chemother 2010, 54:4416-4423.
• [47]Neu HC: Mecillinam––an amidino penicillin which acts synergistically with other beta-lactam compounds. J Antimicrob Chemother 1977, 3(Suppl B):43-52.